Home › Research › Topics › fda-approval
fda-approval
2 studies tagged fda-approval, dated 2023-03-01 to 2026-06-22. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
Studies
2 studies carry this tag.
Date range
2023 to 2026
Top journals
- Health science reports 1
- Lancet regional health. Americas 1
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
Despite the risks of ARIA and other adverse events, Donanemab-azbt represents a promising addition to AD therapy, offering the potential for improved outcomes in patients with early symptomatic disease and expanding the therapeutic options beyond traditional symptomatic treatments.
-
In 2021, the US Food and Drug Administration (FDA) granted approval to aducanumab, an antiamyloid antibody for early-stage Alzheimer's disease, despite a lack of clear clinical evidence demonstrating the drug's cognitive benefits.